Hosted on MSN4h
New Hope for Metastatic Colorectal Cancer Patients: A Targeted Approach With a Drug Called Encorafenib Gets FDA ApprovalA groundbreaking FDA approval has introduced a new treatment option specifically designed for colorectal cancer patients with ...
Novo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate. The FDA approved Eli Lilly ...
The task ahead of Vertex now is to migrate patients already on Trikafta to the new drug. That is supported by data from the ...
Enanta Pharmaceuticals (NETA) stock fell as the company plans to appeal a court ruling favoring Pfizer in a patent dispute ...
Iowa has its first confirmed case of H5N1 bird flu in a poultry farm worker, the state's public health department announced.
The accelerated approval is part of the FDA’s Project FrontRunner, aimed at advancing cancer drug development.
US pharma giant Pfizer on Friday revealed that the US Food and Drug Administration (FDA) has approved its Braftovi ...
Pfizer’s BRAFTOVI combination regimen receives US FDA approval for treatment of metastatic colorectal cancer: New York Monday, December 23, 2024, 10:00 Hrs [IST] Pfizer Inc anno ...
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with ...
Pfizer Inc. (PFE) said that the U.S. Food and Drug Administration has approved BRAFTOVI (encorafenib) in combination with cetuximab ...
Intelligent Living Application Group Inc. (the "Company" or "Intelligent Living"), a premium lockset manufacturer and distributor headquartered in Hong Kong, today announced its unaudited financial ...
Patients with the BRAF V600E mutation and metastatic colorectal cancer (CRC) can be treated with a combination of encorafenib with cetuximab and mFOLFOX6.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback